期刊文献+

EP4对人甲状腺乳头状癌TPC-1细胞生长的影响 被引量:3

Effect of EP4 on the Growth of Human Papillary Thyroid Carcinoma Cell Line TPC-1
下载PDF
导出
摘要 【目的】探讨前列腺素E受体4(EP4)对人甲状腺乳头状癌TPC-1细胞生长的影响。【方法】体外培养人甲状腺乳头状癌细胞株TPC-1及人甲状腺滤泡上皮细胞株Nthy-ori 3-1,Nthy-ori 3-1细胞作为对照,用ELISA法检测细胞上清液中前列腺素E2(PGE2)含量;用实时荧光定量PCR法检测四种前列腺素E2受体亚型(EP1、EP2、EP3、EP4)m RNA表达水平;用Western Blot法检测EP1-4、PKA及PI3K两种亚型(p110α、p110γ)蛋白的表达情况。用噻唑蓝(MTT)比色法检测EP4受体拮抗剂L-161982对两种细胞生长的作用。【结果】两种细胞均分泌PGE2。与Nthy-ori 3-1细胞相比,TPC-1细胞EP2、EP4表达显著上调(P<0.05),EP4下游信号因子PI3K亚型p110α、p110γ蛋白表达升高(P<0.05)。L-161982呈浓度依赖性抑制TPC-1细胞生长(P<0.05)。【结论】EP4受体拮抗剂L-161982可抑制TPC-1细胞生长。 [Objective] To explore the effect of prostaglandin E receptor 4 (EP4) on the growth of human papillapy thyroid carcinoma cell line TPC-1. [Methods] Human papillary thyroid carcinoma cell line TPC-1 and human thyroid follicular epithelial cell line Nthy-ori 3-1 were cultured. ELISA assay was used to measure the level of PGE2 in cell supernatants. The mRNA expression of four EP receptor subtypes (EP1, EP2, EP3 and EP4) was examined by quantitative real-time PCR (qRT-PCR). The levels of EPI-4, PKA and PI3K(p110(1 and p110γ) protein were determined by Western blotting. The effects of selective EP4 antagonist L-161982 on cell viability were determined using MTI' assay. [Results] PGE2 production ean be detected in both TPC-1 and Nthy-ori 3-1 cells. EP2 and EP4 expression appeared to increase in TPC-1 cells compared with Nthy-ori 3-1 cells(P 〈 0.05). Meanwhile, TPC-1 cells expressed elevated protein levels for PI3K isoforms p 110α and p110γ in comparison withNthy-ori 3-1 cells (P 〈 0.05).L-161982 decreased TPC-I cell viability in a dose-dependent manner(P 〈 0.05). [Conclusion] EP4 antagonist L-161982 can inhibit the growth of TPC- 1 cells.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2016年第3期396-401,共6页 Journal of Sun Yat-Sen University:Medical Sciences
基金 2013年珠海市科技计划重点项目(2013D0401990008)
关键词 甲状腺乳头状癌 前列腺素E2 前列腺素E受体4 L-161982 papillary thyroid carcinoma prostaglandin E2 prostaglandin E receptor 4 L-161982
  • 相关文献

参考文献20

  • 1TORRE LA,BRAY F,SIEGEL RL,et al. Globalcancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2):87-108.
  • 2MPH RLS. Cancer statistics, 2015 [J]. CA: A CancerJournal for Clinicians,2015,65 (1 ) : 5—29.
  • 3吴艺捷.甲状腺癌已成为严重的公共健康问题[J].中华内分泌代谢杂志,2015,31(1):1-3. 被引量:34
  • 4SCARPINO S,DURANTI E, GIGLIO S,et al. Papillarycarcinoma of the thyroid : high expression of COX-2 andlow expression of KAI -1/CD82 are associated withincreased tumor invasiveness [J]. Thyroid ,2013,23(9):1127-1137.
  • 5SIIRONEN P, HISTIMAKI A, NARKO K, et al.VEGF -C and COX -2 expression in papillary thyroidcancer[J]. EndocrRelat Cancer,2006,13(2) :465-473.
  • 6LO CY, LAM KY,LEUNG PP, et al. High prevalenceof cyclooxygenase 2 expression in papillary thyroidcarcinoma [J]. Eur J Endocrinol,2005 ,152 (4) : 545 -550.
  • 70,CALLAGHAN G, HOUSTON A. Prostaglandin E2and the EP receptors in malignancy: possibletherapeutic targets [J]? Br J Pharmacol,2015,172(22):5239-5250.
  • 8KONYA V, MARSCHE G,SCHULIGOI R,et al. E-type prostanoid receptor 4 (EP4) in disease and therapy[J]. PharmacolTher,2013,138(3) :485-502.
  • 9SUN L, WEI X, LIU X, et al. Expression ofprostaglandin E2 and EP receptors in human papillarythyroid carcinoma[J]. Tumor Biology,2015.
  • 10O'BANION MK. Cyclooxygenase-2; molecular biology,pharmacology, and neurobiology [J]. Crit RevNeurobiol ,1999,13(1): 45-82.

二级参考文献21

  • 1Pacini F. Management of papillary thyroid mi nocere[ J] ! J Clin Endocrinol Metab, 2013, Malandrino P, Pellegriti G, Attard M, 98(4) et M. 1391-1393.
  • 2Papillary thyroid a comparative study of the characteristics and risk factors at presentation in two cancer registries [ J ]. J Clin Endocrinol Metab, 2013,98(4) :1427-1434.
  • 3Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States [ J ]. Surgery, 2013,154 (6) : 1420-1427.
  • 4Li N, Du XL, Reitzel LR, et al. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: Review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008 [ J ]. Thyroid, 2013,23 ( 1 ) : 103-i 10.
  • 5Leenhardt L, Groselaude P, Chrrir-Challine L. Increased incidence of thyroid carcinoma in France: A true epidemic or thyroid nodulemanagement effects? Report from the French Thyroid Cancer Committee [ J ]. Thyroid, 2004,14 ( 12 ) : 1056-1060.
  • 6Sassolas G, Hafdi-Nejjari Z, Remontet L, et al. Thyroid cancer: is the incidence rise abating [ J ] ? Eur J Endocrinol, 2009,160 ( 1 ) :71-79.
  • 7Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002 [ J]. JAMA, 2006,295:2164-2167.
  • 8Londero SC, Krogdah A, Bastholt L, et al. Papillary thyroid in Denmark 1996-2008: A national study of epidemiology and clinical significance [ J ]. Thyroid, 2013,23 ( 9 ) : 1159-1164.
  • 9Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study[J]. Cancer, 1985,56(3) :531-538.
  • 10Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroidmicrocarcinoma found in autopsy series conducted in areas of different iodine intake[ J]. Thyroid, 2005,15 ( 2 ) : 152-157.

共引文献33

同被引文献16

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部